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Abstract
Background: Non-infectious uveitis is a well-reported cause of blindness in more developed countries, however
data from sub-Saharan Africa is lacking. Here we aim to describe the diseases associated with paediatric non-
infectious uveitis and the effect of currently available treatment in this setting.
Methods: A retrospective observational analysis of children with non-infectious uveitis from January 2010 to
December 2017, attending the tertiary paediatric rheumatology and ophthalmology referral units in Cape Town was
conducted. Statistical analysis utilising STATA13 software was performed with p < 0.05 considered significant.
Results: Twenty-nine children were identified: median age at first visit of 74 months (IQR 49–86 months), female to
male ratio of 0.9:1, predominantly of mixed ancestry (72.4%). Juvenile idiopathic arthritis associated uveitis (JIAU)
(48.3%), idiopathic uveitis (41.4%), sarcoidosis (6.9%) and Behcet’s disease (3.5%) were diagnosed. Chronic anterior
uveitis (72.4%) was the most frequent finding. Fifty-five percent had complications at presentation and all children
with idiopathic uveitis presented with cataracts.
Only 6.5% of the JIA cohort had JIAU. All JIA children had chronic anterior uveitis. There were no differences
between JIA children with uveitis and those without uveitis, for sex (p = 0.68) and race (p = 0.58). Significantly,
children with uveitis presented at an overall younger age (p = 0.008), had oligo-articular JIA (p = 0.01) and were
antinuclear antibody positive (p < 0.001).
Children with idiopathic uveitis were predominantly male (66.6%) with chronic anterior uveitis (41.7%).
Nineteen children (65.5%) in the cohort had inactive disease on treatment at 12 months from diagnosis, which
included 10 on topical corticosteroid therapy. At the last clinical visit 17 (58.6%) on standard initial therapy, 8
(27.6%) on tumour necrosis factor inhibitors and 2 on additional DMARDs were in remission. Five of these children
still required topical corticosteroids. Surgery was performed in 41.4%, primarily in the idiopathic group. Visual acuity
improved or was maintained on treatment.
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Conclusion: Current practice seems to detect children with potentially sight-threatening disease but the high rate
of complications and the low percentage of children with JIAU raises concerns of delayed healthcare intervention.
Tumour necrosis factor inhibitors have improved outcomes in refractory cases in this cohort, however further
studies are needed.
Keywords: Non-infectious uveitis children juvenile idiopathic arthritis sub-Saharan Africa
Background
Uveitis broadly describes inflammation of the iris, chor-
oid and retina, which occurs when the blood-aqueous
and blood-retinal barrier is disrupted. This may be trig-
gered by infectious or non-infectious diseases and is an
important cause of 16–25% of blindness worldwide. The
estimated paediatric prevalence of 28:100000, is at least
4 times lower than in adults [1]. However, the sight-
threatening consequences due to late presentation and
aggressive disease are far-reaching in children, particu-
larly in developing countries where employment oppor-
tunities for the visually impaired are limited [2].
Epidemiology studies highlight the paucity of data from
Africa and other developing countries, noting potential
differences in the prevalence and demographics of under-
lying aetiologies as well as in outcomes [1, 3]. In sub-
Saharan African countries (SSA), uveitis is under-reported
in surveys or studies on blindness in specific regions. In
general, active uveitis resulting in visual loss tends to be
documented and outcomes, rather than the underlying
diseases are recorded [4–8]. Additionally, studies predom-
inantly describe adult populations and infectious diseases
[9–12]. In children, post-streptococcal syndrome and
HIV-associated uveitis have also recently been described
[13–15]. Idiopathic uveitis is diagnosed where an under-
lying systemic cause cannot be found despite diagnostic
ocular paracentesis in some cases. This frequently pre-
sents with complications and still accounts for up to 50%
of uveitis populations seen at referral centres [16–18].
The prevalence of paediatric immune-mediated sys-
temic diseases and the associated uveitis, varies by
underlying disease, disease subtype, as well as geograph-
ically [1]. In SSA, the limited data in children, describe
the association with juvenile idiopathic arthritis (JIA).
Notably BD is reported more frequently from countries
around the Mediterranean basin and the Far East [1,
19–26]. In European and western countries, where the
highest prevalence of JIA is reported, chronic anterior
uveitis occurs in up to 20% of children diagnosed with
the oligo-articular JIA subtype. These are predominantly
ANA positive, young girls under 7 years old of Cauca-
sian ancestry although recently, associations with age
and sex have been questioned [27, 28]. Ancestry as a
predictor of more aggressive disease and poorer out-
comes has also been described but research in this area
is ongoing [29]. While chronic anterior uveitis is associ-
ated with the psoriatic JIA subtype, acute anterior uveitis
may also be seen in those presenting at an older age with
an enthesitis-related arthritis phenotype [30, 31]. How-
ever, acute anterior uveitis is more commonly associated
with enthesitis-related arthritis and psoriatic JIA, as well
as in other HLA B27 associated diseases [27, 32].
The potential risk of amblyopia and poor long-term
outcomes secondary to persistent disease activity and
prolonged corticosteroid treatment in children is recog-
nized. The standard uveitis nomenclature (SUN) work-
ing group classification and screening guidelines, though
not formally validated in children, has improved cross-
study comparisons. This has aided monitoring of treat-
ment responses and decisions to escalate therapy. In-
formed by ongoing studies, treatment recommendations
are further elaborated in recent management guidelines.
[33–46].
Understanding the underlying causes of non-
infectious, immune-mediated uveitis is essential for ap-
propriate management and to improve overall visual
outcomes. However, to date there are no studies review-
ing non-infectious uveitis per se, in children from SSA.
Aim
Here we aim to describe the disease characteristics and
outcomes on immunomodulatory treatment, of children
with non-infectious uveitis managed at a tertiary paedi-
atric referral centre in Cape Town, South Africa.
Methods
Study design
A retrospective case file review of all children ≤16 years
managed for non-infectious uveitis by the paediatric
ophthalmology and rheumatology units in Cape Town
from 1 January 2010 to 31 December 2017 was
conducted.
The tertiary paediatric rheumatology and ophthalmol-
ogy referral units at Groote Schuur and Red Cross Chil-
dren’s Hospitals in Cape Town are the main tertiary
referral centres for the Western Cape as well as other
provinces in South Africa. The Western Cape population
numbers around 6.2 million and children <15years con-
stitute 26% [47]. For the purposes of this study, self-
reported ancestry is considered, as associations with
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potentially higher risk and poorer outcomes have been
described [28, 29].
Data collection
Children with non-infectious uveitis managed by the ter-
tiary referral paediatric ophthalmology and rheumatol-
ogy units were included. Children with JIA were
included if uveitis was found on screening during the
study period. Screening for JIAU was performed at diag-
nosis and at 3 monthly intervals as per the Standard
Uveitis Nomenclature (SUN) working group recommen-
dations [34, 48]. Children were identified from a review
of paediatric rheumatology (PR) and ophthalmology case
files and confirmed on the hospital electronic booking
system. Data of patients identified with non-infectious
uveitis included age, sex, self-reported ancestry, date of
first presentation, anatomical location of uveitis, visual
acuity, (VA) and complications. For uniformity, VA was
converted from the recorded annotation to the log of
the minimal angle of resolution (LogMAR) [49]. Data of
children with JIA additionally included JIA subtype, time
to uveitis diagnosis and arthritis disease activity on
treatment.
JIA was defined as per International League of Associ-
ations for Rheumatology criteria [50]. Idiopathic uveitis
was diagnosed after exclusion of infective and other im-
mune mediated diseases by clinical assessment and la-
boratory tests. These included but were not limited to
toxocara and toxoplasma serology, HIV Elisa or poly-
merase chain reaction (PCR), ANA, anti-double stranded
DNA, anti-streptolysin O (ASO) and, anti-
deoxyribonuclease B (Anti-DNAse B) titres, serum
angiotensin converting enzyme, Treponema Pallidum
Haemagglutination test and/or Venereal Disease Re-
search Laboratory test and urine dipstix. Ebstein barr
virus, cytomegalovirus and Lyme disease (not endemic
in the Western Cape region of South Africa) serology,
were not routinely requested but may have been per-
formed in individual cases. Sarcoidosis was diagnosed
based on clinical presentation, histology +/− raised
serum angiotensin levels and Behcet’s disease by clinical
diagnosis as per the paediatric BD criteria 2015 [51].
Treatment modalities were grouped as standard initial
treatment which included corticosteroids (topical and/or
systemic) and methotrexate 10–20 mg/m2 (maximum
dose 20mg orally or 25 mg subcutaneously). Additional
disease modifying anti-rheumatic drug therapy included
azathioprine (1–3 mg/kg) and mycophenolate mofetil
(250–500 mg/m2 bd). Biologic therapy included TNFi
Infliximab 6–10mg/kg iv infusion monthly (after load-
ing) and Adalimumab 20–40mg subcutaneously every
second week.
The primary outcome was considered as clinically in-
active disease on treatment. Ophthalmology assessments
were performed at weekly to 3-monthly intervals de-
pending on severity of disease. Uveitis activity at 12
months and at the last clinical visit was evaluated. An-
terior chamber disease, vitreous haze and posterior dis-
ease were assessed utilising the SUN criteria [34]: The
response to treatment was defined as a two-step decrease
in inflammation or decrease to Grade 0, active disease as
≥ Grade 1 (6–15 cells/slit lamp field and faint anterior
chamber flare), inactive disease as Grade 0 (< 1 cell/slit
lamp field and no anterior chamber flare) and worsening
of disease activity as a two-step increase in level of in-
flammation or an increase from 3+ to 4+ for anterior
chamber disease. Vitreous haze was further evaluated by
the Nussenblatt 1985 criteria [52] and posterior disease
activity by resolution or non-resolution of retinal vascu-
litis and/or disc swelling.
For this study, remission was defined as ≥3months of
inactive disease on treatment.
The secondary outcome was considered as improve-
ment in visual acuity.
Children managed for < 3 months or were lost to
follow-up, as well as children with proven infectious
uveitis were excluded from the study.
Statistical analysis
Statistical analysis was performed using STATA13
software.
The frequencies of categorical variables were noted
and descriptive statistics employed to determine mea-
sures of central tendency. Chi-squared (or Fisher exact
tests if frequencies were < 5) and t-tests (or Wilcoxon
sum rank tests for non-parametric data) for comparisons
between groups, were used as appropriate to evaluate as-
sociations with p < 0.05 considered significant. Odds ra-
tios for statistically significant variables were calculated
to evaluate associated risk. Cox regression models was
used to assess time to inactive disease and time to uveitis
from JIA diagnosis.
Results
Thirty-four children were referred for the management
of uveitis. 19 (55.9%) presented to ophthalmology and 15
(44.1%) to rheumatology. Five with underlying infectious
causes were excluded, resulting in 29 children meeting
inclusion criteria. The overall group had a 0.9:1 female
to male ratio, median age at first visit of 74 months (IQR
49–86months) and were predominantly of mixed ances-
try (72.4%). Children with JIAU (48.3%) and idiopathic
uveitis (41.4%) most commonly had bilateral, chronic
anterior uveitis (72.4%). Panuveitis (33.4%), acute anter-
ior (6.9%) and intermediate uveitis (3.5%) were less fre-
quent. All children with panuveitis had inflammation of
the anterior chamber and vitreous, with retinal vasculitis
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and/or disc swelling. Fifty-five percent had cataracts at
presentation (Table 1).
For the cohort, the median time from diagnosis to
inactive disease was 7 months (IQR 6–15 months)
(Fig. 1a). Although the median time varied depending
on the underlying disease, there was no statistical dif-
ference (p = 0.28) between children with JIAU and
idiopathic uveitis for overall time to inactive disease
from diagnosis (Fig. 1b). Twenty children were diag-
nosed before 2017. Of these, 19 children had inactive
disease on treatment at time-point 12 months after
diagnosis, including 3 who had been started on TNFi
(Fig. 2). 8 children in the standard treatment group
and 1 on TNFi, no longer required topical steroid
therapy. At the last clinical visit, 27 (93.1%) children
were in remission. One (3.5%) had ongoing refractory
Table 1 Disease characteristics











No. of affected eyes
(CI: 1.6–1.9)





55 (34–86) 76.5 (67–85) 102.5 (49–156) 120 (-)
Female N (%)
(CI: 1.3–1.7)
8 (57.1) 4 (33.3) 2 (100) 0
Ancestry N (%)
(CI: 1.1–1.6)
Mixed 10 (71.4) 9 (75) 1 (50) 1 (100)
Black African 2 (14.3) 2 (16.7) 1 (50) 0
Caucasian 2 (14.3) 1 (8.3) 0 0
Anatomical Location
(CI: 1.3–2.2)
Acute Anterior 0 1 1 0
Chronic Anterior 14 6 0 1
Intermediate 0 1 0 0
Posterior 0 0 1 0
Panuveitis 0 4 0 0
Laterality N (%)
Unilateral 2 4 0 1
Bilateral 12 8 2 0
Complications
(CI 1.0–1.9)
No. affected children (N) 7 9 0 0
Cataracts 5 9 0 0
Posterior synechiae 3 3 0 0
Band Keratopathy 2 2 0 0
Raised intra- ocular pressure 3 4 0 0
VA at presentation (Median)
LogMAR (IQR)
(IQR)
0.1 (0.0–0.3) 0.95 (0.55–2.45) 0.0 (0.0–0.0) 0.3 (−)
VA at last visit
Median LogMAR (IQR) 0 (0.0–0.2) 0.3 (0.0–0.6) 0 (0–0) 0.1 (−)
Change in VA: p-value 0.06 0.001 – –
JIAU Juvenile Idiopathic Arthritis associated Uveitis, CI 95% confidence interval, VA Visual Acuity, LogMAR Log of minimal angle of resolution, where LogMAR 0.0
~ Snellen 6/ 6, LogMAR 0.5 ~ Snellen 6/19 and LogMAR 1.0 ~ Snellen 6/60
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disease and 1 (3.5%) had clinically inactive disease for
< 3 months (Table 2). Twenty-two children no longer
required topical steroid therapy. However, 2 children
recently diagnosed with JIAU in the standard treat-
ment group and 3 with idiopathic uveitis in the TNFi
group, still required topical steroid therapy.
There was an overall clinical improvement in visual
acuity (VA) (Table 1).
Disease characteristics
Children with JIAU were most commonly female (female
to male ratio of 1:0.75), had a median age of 55 months
(IQR 34–86months), and were predominantly of mixed
ancestry (71.4%). All children had chronic anterior uve-
itis (100%).
Further analysis in relation to the overall JIA cohort
managed during the study period was undertaken
(Table 3). A total of 229 patients were assessed for JIA
of which 12 were excluded according to ILAR criteria.
The remaining 217 were evaluated, with a consequent
JIAU clinic prevalence of 6.5%. Three children had uve-
itis for 12, 9 and 4months prior to the diagnosis of JIA.
The majority developed uveitis within a year of diagnosis
(Fig. 3). Comparisons for sex (p = 0.68) and ancestry
(p = 0.58) were not statistically significant. Children older
than 144 months were not diagnosed (p = 0.01) with
uveitis. Young age ≤ 84 months (p = 0.01), oligo-JIA sub-
type (p = 0.01) and positive ANA (p < 0.001) were signifi-
cant factors. Univariate analysis showed odds ratios (OR)
for possible risk factors associated with uveitis as oligo-
articular subtype (OR 4.45 CI 1.35–14.7) and positive
ANA (OR 33.3, CI 6.83–162.09). Seven (50%) children
had complications. Reduced VA at presentation was due
to cataracts in 5 children. There was no statistical differ-
ence in complications between those diagnosed with
uveitis before arthritis and those with uveitis on screen-
ing at diagnosis and subsequently (p = 0.28). At time-
point 12 months from diagnosis, 9 (64.3%) children on
standard initial treatment and one on TNFi had inactive
disease. By the end of the study period, 8 (57.1%) were
in remission on standard initial treatment, 2 (14.3%) on
additional DMARDs and the previously refractory 4
(28.6%) on TNFi treatment. Of children treated with
TNFi, 3 were originally commenced on infliximab and 2
were switched to adalimumab due to lack of efficacy. Of
these, one was diagnosed with uveitis 12 months before
arthritis. The one child on infliximab and all children in
the adalimumab group achieved remission. Three chil-
dren had cataract surgery.
Idiopathic uveitis (41.4%) was the next frequent diag-
nosis, presenting in males (66.6%), at a median age of
76.5 months (IQR 49–156 months) who were of of
Fig. 1 a: Time to inactive disease. b: Time to inactive disease by diagnosis
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Pre-JIA diagnosis N = 3
Standard Initial Rx 29 R 7 1 6 2 1 17 (58.6)
NR 4 2 6 0 0 12 (41.4)
Azathioprine 8 R 1 – 0 – – 1 (12.5)
NR 3 – 4 – – 7 (87.5)
Mycophenolate Mofetil 3 R 1 – 0 – – 1 (33.3)
NR 1 – 1 – – 2 (66.6)
Infliximab 6 R 1 0 1 – – 2 (33.3)
NR 1 1 1 – – 3 (50)
Adalimumab 8 R 1 2 4 – – 7 (87.5)
NR 0 0 1 – – 1 (12.5)
Surgery: no. of children N (%) 2 1 9 0 0 12 (41.4)
No. of procedures
Cataract incl. Pars planar vitrectomy/ lensectomy 2 1 10 0 0 13
Corneal chelation 0 0 2 0 0 2
Evisceration 0 0 1 0 0 1
Responders (R) had inactive disease on treatment. In non-responders (NR), treatment was escalated to one of the additional DMARDs then a TNFi or directly to
a TNFi
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mixed ancestry (75%). Both eyes were affected in 66.6%
with chronic anterior uveitis (50%). All children pre-
sented with cataracts and had a median VA LogMAR
0.95 (0.55–2.45). Four children (33.3%) had inactive dis-
ease on standard initial treatment and 2 (16.7%) on TNFi
at 12 months. At the last clinical visit, 6 (50%) were in
remission on standard initial treatment, 1 (8.3%) on
infliximab and 4 (33.3%) on adalimumab. 75% of chil-
dren required cataract surgery. One child did not re-
spond to therapy, was ANA positive and needed
evisceration of one eye due to painful glaucoma. The
overall improvement in VA for the remaining children
was statistically significant (p = 0.001).
Sarcoidosis (6.9%) was diagnosed in 2 females. Both
had bilateral uveitis and no complications at presenta-
tion. They had inactive disease by 12 months, achieved
remission on standard initial therapy and had preserved
vision.
The 120 month old male of mixed ancestry with BD,
presented with unilateral chronic anterior uveitis, had no
complications and responded to standard therapy within
3 months.
Discussion
Non-infectious immune-mediated uveitis remains an im-
portant cause of ocular morbidity in children and des-
pite some advances in the understanding of the
underlying pathophysiology, sight-threatening complica-
tions are still frequently reported [53, 54]. The dearth of
literature from Africa and other developing countries,
reinforces the perception that immune-mediated dis-
eases are rare or non-existent in children from this set-
ting. Although this assumption has recently been
challenged [55–58], advocacy for treatment strategies
deemed too expensive, regardless of proven efficacy else-
where, is still hindered.
Table 3 Comparison of JIA with no uveitis and with uveitis (JIAU)










Age groups (months) N (%) Odds Ratio 95% CI
0–84 70 (32.3) 60 (29.6) 10 (71.4) †p = 0.01 0.46 CI 0.25–0.83
85–144 73 (33.6) 69 (33.9) 4 (28.6) p = 0.78 0.71 CI 0.22–2.35
145–192 60 (27.7) 60 (29.6) 0 †p = 0.01 1.0 CI 0.6–1.7
Female N (%) 135 (62.2) 127 (62.5) 8 (57.1) p = 0.68 0.78 CI 0.26–2.34
Ancestry N (%)
Mixed 124 (57.1) 114 (56.2) 10 (71.4) p = 0.40 0.72 CI 0.39–1.3
Black African 37 (17.1) 35 (17.2) 2 (14.3) p = 1.00 1.25 CI 0.27–5.8
Caucasian 56 (25.8) 54 (26.6) 2 (14.3) p = 0.53 0.46 CI 0.10–2.1
JIA subtype N (%)
Oligo-articular 83 (38.3) 73 (35.9) 10 (71.5) †p = 0.01 4.45 CI 1.35–14.7
Poly articular RF + 18 (8.3) 18 (8.8) 0 p = 0.61 0.08 CI 0.04–0.13
Poly articular RF – 43 (19.8) 40 (19.7) 3 p = 1.00 1.05 CI 0.54–2.04
Psoriatic 16 (7.4) 15 (7.4) 1 p = 1.00 0.99 CI 0.59–1.66
Systemic Onset JIA 17 (7.8) 17 (8.4) 0 p = 0.61 –
Enthesitis Related Arthritis 38 (17.5) 38 (18.7) 0 p = 0.14 –
Undifferentiated 2 (0.9) 2 (1) 0 p = 1.00 –
Lab Parameters N (%)
ANA tested 147 (67.7) 136 (67) 11 (78.6) †p < 0.001 33.29 CI 6.83–162.09
Hep2 Positive 15 10 5
Elisa Positive 15 9 6
RF tested 125 (57.6) 116 (57.1) 9 (64.3) p = 0.36 –
Negative 107 98 9









p = 1.00 –
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Here, we have shown that the spectrum and disease
characteristics associated with non- infectious uveitis are
comparable in some respects to that of more developed
countries but are dissimilar to reports from North Af-
rica, where BD [24, 25] is more common. Importantly,
54.5% of our cohort presented with easily identifiable
cataracts and posterior synechiae, attesting to significant
delays in diagnosis. The inequitable distribution of
health care resources, socioeconomic factors, health
seeking behaviour and lack of expertise in key areas,
Fig. 3 Time to uveitis from JIA diagnosis
Table 4 Comparison of SSA and developed countries




Kenya (63) Nigeria (21) Canada (61) Atlanta (27)
Single / Multi-centre Single Single Single Single Single Multi Single
Total N 217 97 85 68 28 1183 287
JIA subtypes (%)
Oligo 38.3 39 32.1 23.5 39.3 40 46
Poly RF– 19.8 30 34.6 38.2 42.8 20 24.4
Poly RF+ 8.3 9 11.5 17.6 7.1 4 4.5
ERA 17.5 5 6.4 5.9 0 14 12.9
Psoriatic 7.4 0 1.3 0 0 6 3.5
SJIA 7.8 16 14.1 14.7 17.9 6 7.7
Undifferentiated 0.9 0 0 0 0 10 0.7
Uveitis (%) 6.5 4 12.8 1.5 7.1 8.5 18.2
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contribute in varying degrees to delayed access to care
in South Africa and likely resulted in late presentation to
our unit [59, 60].
Juvenile idiopathic Arthritis
Comparison with two studies from developed countries
(Table 4), the large multicentre Canadian Research in
Arthritis in Canadian Children emphasizing Outcomes
(ReaCCH-out) study cohort and a single centre Atlanta
study [27, 61], showed similarities in median age of JIA
presentation, relative frequencies of poly-articular RF
negative JIA subtype and ANA positivity. However, an
older age at JIAU presentation and a lower frequency of
oligo-articular JIA is seen in our cohort. The prevalence
of JIAU here (6.5%) is also lower than reported in those
studies (8.5% and 18%), as well as other developed coun-
try descriptions of up to 20% [62]. Paediatric rheumatol-
ogy is a relatively new sub-speciality in South Africa,
with a formal training program only established within
the last 10 years. Under-recognition and lack of referral
may play a role in the low frequency of JIA cases re-
ported here. This seems to be in keeping with the few
published studies from SSA [14, 20, 21, 63].
The chronic anterior uveitis, presenting at a younger
mean age, significantly in the ≤ 84-month age group (p
= 0.001), also fits more developed country descriptions
[62]. The majority of children with JIAU were ANA
positive (78.6%). However, this is in contrast to previous
studies from South Africa, where children with uveitis
had polyarthritis and were ANA negative [14, 19].
Whether ancestry has an influence on these differences
is uncertain. Further prospective studies to elucidate the
role of sex, ancestry, JIA subtype and positive ANA, is
needed.
A high percentage (21.4%), compared to the 3–7%
generally described [48], developed uveitis before arth-
ritis was diagnosed. Eleven were detected on screening
and half presented with complications, 71.4% of which
were cataracts. This raises further concerns of diagnostic
delays in our setting. Notably, treatment was escalated
to manage uveitis as arthritis was in remission.
Idiopathic uveitis
In our study, idiopathic uveitis (36.3%) had a relatively
lower frequency, reflecting the small number of referred
patients likely for reasons as previously discussed. As in
other descriptions, refractory disease with chronic anter-
ior and panuveitis, complications and the need for sur-
gery is noted. Similar severity and poorer outcome were
reported in black South African children in historical
studies [64–66], prior to the availability of TNFi. Here,
children with refractory disease showed significant im-
provement in disease activity and VA on TNFi
treatment.
Sarcoidosis is rare in children and may affect the uveal
tract. Both children in our study responded well to sys-
temic corticosteroid treatment and methotrexate. Escal-
ation to TNFi was not needed here, as has been reported
in other studies [67–71].
Paediatric BD is rarely reported from SSA although
adult case series highlight severe skin and ocular mani-
festations [72, 73]. In contrast to paediatric case series
from North Africa [24, 73], our patient had few recur-
rences, no complications and near normal vision at the
last clinical assessment. HLAB51 was not done here.
Other immune mediated diseases including Vogt
Koyanagi Harada syndrome, tubulointerstitial nephritis
associated uveitis, uveitis with SLE and other autoin-
flammatory disorders were not represented in this study.
Treatment outcome
Overall, remission on standard initial uveitis treatment
(58.6%) endorses its use as first line therapy in our re-
source limited setting. Azathioprine and MMF were
used less frequently due to gastrointestinal adverse ef-
fects and perceived lower efficacy. Neither cyclosporine
nor intraocular corticosteroid injections were used in
our cohort, as low evidence and side effect profile in
young children were considered to outweigh the benefit
[37, 46, 74, 75]. TNFi were only used in refractory cases
due to availability and cost and showed good efficacy.
Infliximab has been shown to be safe and efficacious in
children with refractory disease [76, 77]. Here, infliximab
was successfully used in 2 patients, while one switched
to adalimumab due to lack of efficacy and another due
to an adverse reaction to the infliximab infusion. Adali-
mumab was used in conjunction with methotrexate in
all our patients with good effect. The small sample size
limits inferences that can be made from this study but
previous studies [26, 39, 40, 78] have shown good out-
comes. The use of DMARDs and biologic therapy,
allowed successful discontinuation of topical corticoster-
oid therapy in the majority of children. Further research
into the efficacy of these agents in our setting is needed.
Five children with visually significant uveitic cataracts
underwent lensectomies, together with pars plana vitrec-
tomies (PPV), as is standard practice at our institution.
This was due to the presence of associated vitritis or cycli-
tic membranes, which could only be removed by PPV.
Selection bias
Not all children with immune-mediated uveitis may have
been referred, thus community prevalence is not
reflected. Children with JIA are routinely assessed for
uveitis screening and may be over-represented in this
sample.
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Limitations
This retrospective case file review was dependent on the
availability and accuracy of the medical records
reviewed.
The small sample size limits inferences that can be
made from these results.
Conclusion
Current practice seems to detect children with poten-
tially sight-threatening non-infectious uveitis, however
the low percentage of children with JIAU and the high
rate of complications at presentation, raises concerns of
delays in accessing appropriate healthcare. The use of
DMARDs and tumour necrosis factor inhibitors in re-
fractory cases, have improved outcomes in this cohort.
Further prospective studies are needed to establish the
role of associated risk factors, particularly in JIAU and
the efficacy of TNFi.
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